Cargando…
Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study
BACKGROUND: Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β-1a (sc IFN β-1a) and records objective adherence data. The CORE study was unde...
Autores principales: | Zecca, Chiara, Disanto, Giulio, Mühl, Sarah, Gobbi, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584024/ https://www.ncbi.nlm.nih.gov/pubmed/28870152 http://dx.doi.org/10.1186/s12883-017-0952-9 |
Ejemplares similares
-
Evolution of the RebiSmart(®) Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis
por: Lin, Yu-Ting, et al.
Publicado: (2023) -
Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis
por: Sauri-Suárez, Sergio, et al.
Publicado: (2020) -
An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device
por: Willis, Helen, et al.
Publicado: (2014) -
Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study
por: Deftereos, Spyros N., et al.
Publicado: (2018) -
Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
por: Fernández, O., et al.
Publicado: (2016)